- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05841862
Intravitreal Quantum Dots (QD) for Advanced Retinitis Pigmentosa (RP) (QUANTUM)
May 3, 2023 updated by: 2C Tech Corp
Intravitreal Quantum Dots (QD) for Advanced Retinitis Pigmentosa (QUANTUM): a Pilot, Randomized, Double-masked, Sham-controlled, Clinical Device Trial
Pilot, randomized, observer and participant masked, sham and fellow eye controlled, interventional clinical device trail to evaluate the safety and effectiveness of the 2C-QD device to improve visual function in adults with advanced Retinitis Pigmentosa (RP).
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
Subjects will be informed about the study and potential risks and benefits, and then will provide written informed consent prior to study procedures being performed.
Subjects will be screened for eligibility against criteria set forth within the clinical protocol.
If subjects are eligible, they will be randomized to receive an intravitreal injection of the 2C-QD device in one eye, and the fellow eye will receive a sham injection and serve as the control.
Subjects will then be following for 180 days, through 9 visits.
Study Type
Interventional
Enrollment (Anticipated)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Astrid Berthe
- Phone Number: (949) 461-1080
- Email: aberthe@2ctechcorp.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Male or female adults, aged 18 years or older on the day of screening
- Clinical diagnosis of bilateral RP, based on two or more of the following: clinical features, visual field testing, retinal imaging, electrophysiological measures, or genetic testing
- BCVA of 6/60 (logMAR 1.0) or worse in both eyes, with loss of vision due to RP in the opinion of the Investigator.
- Central visual field of less than 20 degrees in both eyes
- Be able to follow instructions and ambulate
- Be able to complete at least one mobility course at highest luminance level using each eye separately
- Be able and willing to provide written informed consent, attend all scheduled visits and comply with all study procedures
- For females capable of becoming pregnant, agree to have urine pregnancy testing (must be negative) and must not be lactating; and must agree to use a medically acceptable form of birth control throughout the study duration. Women considered capable of becoming pregnant include all females who have experienced menarche and have not experienced menopause (as defined by amenorrhea for greater than 12 consecutive months) or have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy). Acceptable forms of birth control are spermicide with barrier, oral contraceptive, injectable or implantable method of contraception, transdermal contraceptive, intrauterine device, or surgical sterilization of partner. For non-sexually active females, abstinence will be considered an acceptable form of birth control.
Exclusion Criteria:
- Presence of severe systemic disease resulting in a life expectancy shorter than 1 year
- Presence of retinal or optic nerve disease other than RP in either eye including cystoid macular oedema (CMO), glaucoma or ocular hypertension (IOP≥ 25mmHg), diabetic retinopathy, retinal vein occlusion, and age-related macular degeneration.
- Be currently using any topical therapy for CMO (e.g., carbonic anhydrase inhibitors, corticosteroids, NSAIDs) in either eye.
- Have the presence of an ocular media opacity in either eye, which in the opinion of the Investigator, will preclude an accurate evaluation at any time during the study
- Have the presence of active ocular or systemic infection or inflammation, or any history of intraocular inflammation in either eye
- Have had a prior vitrectomy in either eye
- Have a history of amblyopia in either eye
- Have current or former high myopia (>6 dioptres) in either eye
- Have undergone ocular surgery within 6 months of the screening visit in either eye or have planned ocular surgery in either eye
- Have one eye that is ineligible, or have asymmetrical ocular disease defined as a greater than 15 letter difference between the eyes based on BCVA results.
- Have participated in any study involving an investigational drug or device within the past 30 days or have ongoing participation in a study with an investigational drug or device or have participated in a clinical trial of gene or cell therapy at any time
- Have any clinical evidence that the Investigator feels would place the subject at increased risk with the investigational product
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 2C-QD
Single-dose intravitreal injection
|
Quantum Dot
|
Sham Comparator: Sham 2C-QD
Single-dose intravitreal injection
|
Sham Intravitreal Injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Monocular navigation performance
Time Frame: baseline to week 2
|
measured based on the ability to navigate the course under different light levels (defined as luminance) using the mobility course.
|
baseline to week 2
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Monocular navigation performance
Time Frame: baseline to week 4, 12, 24, 52
|
measured using luminance level to complete the mobility course
|
baseline to week 4, 12, 24, 52
|
binocular navigation performance
Time Frame: baseline to week 2, 4, 12, 24, 52
|
measured using luminance level to complete the mobility course
|
baseline to week 2, 4, 12, 24, 52
|
monocular retinal sensitivity
Time Frame: baseline to week 2, 4, 12, 24, 52
|
measured using Octopus full-field static perimetry
|
baseline to week 2, 4, 12, 24, 52
|
monocular best-corrected visual acuity (BCVA)
Time Frame: baseline to week 2, 4, 12, 24, 52
|
change in BCVA
|
baseline to week 2, 4, 12, 24, 52
|
ellipsoid zone area
Time Frame: baseline to week 2, 4, 12, 24, 52
|
measured using spectral domain (SD) optical coherence tomography (OCT)
|
baseline to week 2, 4, 12, 24, 52
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Timothy Jackson, Professor, Kings College Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
March 1, 2024
Primary Completion (Anticipated)
March 1, 2025
Study Completion (Anticipated)
March 1, 2025
Study Registration Dates
First Submitted
April 24, 2023
First Submitted That Met QC Criteria
April 24, 2023
First Posted (Actual)
May 3, 2023
Study Record Updates
Last Update Posted (Estimate)
May 4, 2023
Last Update Submitted That Met QC Criteria
May 3, 2023
Last Verified
April 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2C Tech-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Retinitis Pigmentosa
-
MeiraGTx UK II LtdSyne Qua Non Limited; Bionical EmasCompletedGene Therapy for X-linked Retinitis Pigmentosa (XLRP) - Retinitis Pigmentosa GTPase Regulator (RPGR)X-Linked Retinitis PigmentosaUnited Kingdom, United States
-
Oslo University HospitalRecruitingRetinitis Pigmentosa | Retinitis Pigmentosa 11Norway
-
Jinnah Burn and Reconstructive Surgery Centre,...The Layton Rahmatullah Benevolent Trust (LRBT) Free Eye Hospital, Township... and other collaboratorsRecruitingRetinitis Pigmentosa (RP)Pakistan
-
AbbVieActive, not recruitingAdvanced Retinitis PigmentosaUnited States
-
jCyte, IncCalifornia Institute for Regenerative Medicine (CIRM)CompletedRetinitis Pigmentosa (RP)United States
-
Janssen Research & Development, LLCJanssen Research & Development, LLCActive, not recruitingX-Linked Retinitis PigmentosaBelgium, Canada, United States, Israel, United Kingdom, Spain, Denmark, France, Italy, Netherlands, Switzerland
-
Janssen Research & Development, LLCActive, not recruitingX-Linked Retinitis PigmentosaUnited States, United Kingdom
-
GenSight BiologicsRecruitingNon-syndromic Retinitis PigmentosaUnited States, France, United Kingdom
-
Janssen Research & Development, LLCJanssen Research & Development, LLCActive, not recruitingX-Linked Retinitis PigmentosaUnited States, Canada, Israel, United Kingdom, Spain, Denmark, France, Belgium, Italy, Netherlands, Switzerland
-
BiogenCompletedX-Linked Retinitis PigmentosaUnited States, United Kingdom
Clinical Trials on 2C-QD
-
Genus Oncology, LLCCompletedSolid TumorsUnited States
-
Beth Israel Deaconess Medical CenterDana-Farber Cancer InstituteActive, not recruitingRecurrent Adult Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
Chang Gung Memorial HospitalCompletedPeripheral Pulmonary LesionsTaiwan
-
Lexicon PharmaceuticalsCompletedRheumatoid ArthritisUnited States
-
PfizerTerminatedParkinson's Disease With Motor FluctuationsUnited States
-
Kowa Research Institute, Inc.CompletedHyperlipidemiaUnited States
-
PfizerCompletedWeight Management | Treatment Of ObesityCanada, United States, Bulgaria, Spain, Mexico, India, Puerto Rico
-
PfizerWithdrawnUlcerative ColitisUnited States
-
Galapagos NVCompletedIdiopathic Pulmonary FibrosisUnited Kingdom, Ukraine